New diabetes drug showdown: which pill protects senior muscle better?
NCT ID NCT07323381
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at two common diabetes pills—henagliflozin and metformin—to see how they affect muscle mass and blood sugar in older adults (ages 60-85) who are newly diagnosed with type 2 diabetes. About 116 participants will take one of the two medicines daily for 24 weeks. The goal is to find out which drug better preserves muscle while controlling diabetes, helping seniors stay stronger and healthier.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your genes may decide if metformin works for you
- Could a Low-Calorie diet and Weight-Loss drug send type 2 diabetes into remission?
- Could immune cells in fat hold the key to Obesity-Related diseases?
- Your DNA may determine if Weight-Loss drugs work — a trial hunts for clues
- Can a smartphone app and wearable help tame type 2 diabetes?
- Diabetes and antibiotics: a risky mix for the heart?